Retransmission: CTT Pharma and Johns Hopkins University Submits Proposal for $15 Million NIH Grant for Smoking Cessation

Rhea-AI Summary

CTT Pharmaceutical Holdings (OTC:CTTH) and Johns Hopkins University have submitted a proposal for a $15 million NIH Grant to develop a smoking cessation product using CTT's patented technology. The NIH will review the proposal in April 2025.

The proposed product features fast-acting dissolvable nicotine strips that use less nicotine per dose compared to Nicorette gum and dissolve in seconds rather than 30 minutes. CTT plans to price the product competitively at or below Nicorette gum prices.

According to the World Health Organization, tobacco kills over 8 million people annually worldwide. The CDC reports smoking as the leading preventable cause of death in the United States, causing 480,000 deaths yearly. Johns Hopkins University will oversee the clinical trials if the grant is approved.

CEO Ryan Khouri has been invited to appear on Fox Business and Bloomberg regarding this grant and previously spoke at an FDA/NIH hearing about advancing smoking cessation technology.

TAMPA, FL / ACCESS Newswire / January 28, 2025 / CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) and Johns Hopkins University have successfully submitted our proposal for a NIH Grant that will utilize CTT's patented technology as a smoking cessation product. This grant will allow for clinical trials to be conducted and up to $15 million given to cover these trials. The NIH will begin the review process of this proposal in April 2025 and will notify Johns Hopkins University and CTT Pharma of the results. The CEO of CTT Pharma, Ryan Khouri stated, "This brings us one step closer to helping smokers quit, as 480,000 Americans die every year or 1300 per day from the effects of smoking. The last oral nicotine product that was FDA Approved for smoking cessation was Nicorette gum in 1984. While Nicorette gum has helped many people quit smoking, I believe consumers need more options to quit. CTT's fast acting dissolvable nicotine strips would use substantially less nicotine per dose compared to Nicorette Gum and also dissolve in seconds compared to the gum staying in the mouth for 30 minutes. I also want to price our patented technology at or below the price of Nicorette gum, as pricing of our product should not be a deterrent for a consumer looking to quit smoking. Upon approval from the NIH I'm confident in our teams ability to execute our technology and do not anticipate any problems arising. Johns Hopkins University will be in charge of the clinical trials from start to finish. This past October I attended and briefly spoke at a FDA/NIH hearing about advancing smoking cessation technology. I personally met with many individuals who work for both the FDA and NIH and had productive conversations. Furthermore, I have been asked to appear on Fox Business and Bloomberg for interviews in regards to this grant and have interest in doing both shows. I would prefer to do these interviews once our proposal has been approved but I'm considering doing them beforehand. I firmly believe CTT Pharma's dissolvable nicotine strips are a viable solution to a worldwide problem and should be used as a tool to get people to stop smoking." The World Health Organization states, "The tobacco epidemic is one of the biggest public health threats the world has ever faced, killing over 8 million people a year around the world. More than 7 million of those deaths are results of direct tobacco use while 1.3 million are the result of non-smokers being exposed to second-hand smoke." The CDC says, "Cigarette smoking is the leading cause of preventable death in the United States. Cigarette smoking causes more than 480,000 deaths each year in the United States. This is nearly one in five deaths." CTT will continue to update shareholders as more news becomes available.

Investor Relations - 813-606-0060

SOURCE: CTT Pharmaceutical Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the value of the NIH grant CTT Pharma (CTTH) is seeking for smoking cessation?

CTT Pharma and Johns Hopkins University have submitted a proposal for a $15 million NIH grant to develop and conduct clinical trials for their smoking cessation product.

How does CTT Pharma's nicotine strip technology differ from Nicorette gum?

CTT's nicotine strips use less nicotine per dose and dissolve in seconds, compared to Nicorette gum which stays in the mouth for 30 minutes.

When will the NIH review CTT Pharma's (CTTH) grant proposal?

The NIH will begin reviewing CTT Pharma's grant proposal in April 2025.

How many deaths are caused by smoking annually according to the CDC?

According to the CDC, cigarette smoking causes more than 480,000 deaths each year in the United States, nearly one in five deaths.

What is CTT Pharma's (CTTH) pricing strategy for their nicotine strips?

CTT Pharma plans to price their nicotine strips at or below the price of Nicorette gum to ensure pricing is not a deterrent for consumers looking to quit smoking.

Who will conduct the clinical trials for CTT Pharma's smoking cessation product?

Johns Hopkins University will be in charge of conducting the clinical trials from start to finish if the NIH grant is approved.